Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02074930
Other study ID # LPrep
Secondary ID
Status Completed
Phase N/A
First received February 17, 2014
Last updated April 14, 2014
Start date February 2014

Study information

Verified date April 2014
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

It is an open-label physiological investigation of the allergic skin reactivity to epicutaneous allergen exposition in 20 allergic patients in two different skin conditions. The focus of the study is on the skin preparation/condition and not on the specific allergen or allergy, but for reasons of homogeneity a single allergic disease, birch pollen allergy was chosen as the basis for the testing. In order to evaluate the effects of the two different skin preparation techniques an intraindividual comparison of the skin reactivity in terms of the immediate phase I reaction to serial dilutions of birch pollen extracts was chosen. The serial dilution approach allows a dose dependent effect evaluation and comparison of the sensitivity. The differences will be explained mainly by the two different skin preparations allowing a quantitative comparison of these techniques.


Description:

The Objective is the determination of the allergic skin reactivity to epicutaneoulsy applied birch pollen allergen extract after skin preparation (microporation by P.L.E.A.S.E. Professional) and standard skin prick test. By using the standard prick test the stratum corneum is overcome by a single puncture (1 mm).

Micropores induced by P.L.E.A.S.E. Professional penetrate the stratum corneum less deep but with a higher density (five pores). It is therefore suggested that a skin preparation with micropores by P.L.E.A.S.E. Professional previously to the allergen contact may lead to a higher sensitivity. Less allergen might still elicit a skin reaction which won?t be seen by a conventional prick skin test. Whereas skin prick test may lead to true-negative (patient shows no allergic reaction on prick skin test but is an allergy sufferer in clinic), IgE-determination may lead to false-positives (patient is determined as allergy sufferer but has no clinical symptoms). So the sensitivity with micropores skin preparation by P.L.E.A.S.E. Professional could be a good compromise. The preparation of the skin with P.L.E.A.S.E. Professional leads to a better understanding of the influence of different types of skin injury patterns on the allergic skin reactivity. Namely, how important is the role of the exposed area, the depth of injury and the keratinocyte activation.

This will be checked in a late phase reaction evaluation.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date
Est. primary completion date April 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Written informed consent,

- 18-65 years old (male or female),

- a positive clinical history for inhalant allergy presumably due to birch pollen,

- positive screening prick test (mean wheal diameter bigger or equal than 3mm) to birch pollen allergen solution,

- a mean wheal size of bigger or equal than 7mm2 obtained in the screening prick test with histamine dihydrochloride (10mg/ml)

Exclusion Criteria:

- Impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent,

- enrolment into a clinical trial within last 4 weeks,

- pregnancy or nursing,

- positive skin reaction in the screening prick test to NaCl,

- currently suffering from allergy symptoms,

- history of systemic reactions to allergens,

- severe diseases influencing the results of the present study by discretion of the investigator,

- immunotherapy with the allergen preparation during the past two years,

- skin lesions and excessive hair-growth in the skin test areas,

- treatment with prohibited concomitant medications with the exception of medications with local effects which will not influence the results of the skin prick tests,

- known or suspected non-compliance, drug or alcohol abuse

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Intervention

Device:
Microporation by P.L.E.A.S.E. Professional / Prick needle


Locations

Country Name City State
Switzerland University Hospital Zurich, Division of Dermatology Zurich ZH

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wheal Size (mm^2) The minimal protein concentration eliciting a wheal size of >0mm^2 will be compared between the two different skin preparation techniques with a Wilcoxon signed ranks test. The primary outcome will be assesed after 15min after allergen exposure No
Secondary Wheal Size The wheal sizes at 10 HEP, 1 HEP, 0.1 HEP and 0.01 HEP/ml will be compared between the two skin preparation techniques (either with a paired-samples t-test if normally distributed or with a Wilcoxon signed ranks test). Wheal size will be assessed after 15 Minutes No
See also
  Status Clinical Trial Phase
Completed NCT06037148 - Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants Phase 1
Completed NCT04912076 - S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen Phase 1
Recruiting NCT05346718 - Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis N/A
Completed NCT01137357 - Probiotics for Reduction Of Markers In Subjects With Allergy N/A
Active, not recruiting NCT05668390 - Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma Phase 3
Not yet recruiting NCT02146300 - Effect of the Nasal Provocation on the Breathing Style N/A
Completed NCT01449786 - Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy Phase 2
Completed NCT03969849 - Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants Phase 1
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT01628484 - Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation Phase 1
Completed NCT00932607 - SUBLIVAC® Birch PROBE Study Phase 2
Completed NCT00266526 - Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV Phase 2
Completed NCT02143583 - Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment Phase 2
Completed NCT04266028 - Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy Phase 1
Completed NCT00309062 - Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis Phase 3
Completed NCT01675791 - A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet Phase 2